2024年9月期通期の業績予想については、売上高が前期比28.5%増の8.50億円、営業損失が14.88億円、経常損失が14.75億円、当期純損失14.79億円とする期初計画を据え置いている。Medinet ＜2370＞ announced financial results for the 3rd quarter (23/10/24 to 6/24) of the fiscal year ending 2024/9 on the 9th. Sales increased 19.8% from the same period last year to 0.589 billion yen, operating loss was 0.996 billion yen (loss of 1.046 billion yen in the same period last year), ordinary loss was 0.948 billion yen (loss of 1.043 billion yen), and quarterly net loss was 0.951 billion yen (loss of 1.045 billion yen).
Sales in the cell processing business increased 19.9% from the same period last year to 0.589 billion yen, and sales expenses etc. aimed at expanding cell processing contracts increased, and segment loss was 0.245 billion yen (loss of 0.242 billion yen in the same period last year). We are actively developing activities to expand our three business areas (specific cell processed product manufacturing, CDMO business, value chain business). In this 3rd quarter cumulative period, sales have increased in the specific cell processed product manufacturing industry due to a recovery in the number of immune cell processing contracts, price revisions with some business partners, lump-sum technology transfer payments, etc. for manufacturing contracts, etc., and in the CDMO business due to price revisions for manufacturing contract fees, etc.
Sales in the regenerative medicine products business decreased 45.2% to 0 billion yen, and segment loss was 0.316 billion yen (loss of 0.358 billion yen) due to a decrease in research and development expenses. In addition to aiming for early monetization of regenerative medicine products, etc., they are also paying attention to development trends of regenerative medicine products carried out domestically and internationally, and are carrying out activities with a view to acquiring and expanding these pipelines.
As for the full-year earnings forecast for the fiscal year ending 2024/9, the initial plan for sales is 850 million yen, up 28.5% from the previous fiscal year, operating loss is 1,488 billion yen, ordinary loss is 1,475 billion yen, and net loss of 1,479 billion yen remains unchanged.
